ProCE Banner Activity

A Year in Review: ADCs Targeting TROP-2 in NSCLC

Slideset

In this downloadable slideset, review an expert’s perspective on the clinical implications of emerging data on TROP-2–directed antibody–drug conjugates as monotherapy or in combination with immune checkpoint inhibitors and chemotherapy on NSCLC management.

Released: January 29, 2024

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.